Inakalant is used as an atrial-selective potassium channel blocker with antiarrhythmic activity; it prolongs the action potential duration (APD) in cardiac myocytes and increases the effective refractory period in the atria and ventricles, thereby helping to terminate and prevent atrial fibrillation (AF) and other arrhythmias; it is also used in research on cardiac arrhythmias and cardiac electrophysiology.